Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20184163 | 1.00 | KDM4E (0.58) | KDM4EEPHX2OPRM1ESR1TBXAS1 | |
| SCHEMBL6338925 | 1.00 | KDM4E (0.58) | KDM4EEPHX2OPRM1ESR1TBXAS1 | |
| SCHEMBL21548772 | 0.87 | KDM4E (0.46) | KDM4EOPRM1CCNB2CDK1CDK4 | |
| SCHEMBL14032639 | 0.83 | EPHX2 (0.47) | KDM4EEPHX2TBXAS1CYP3A4CYP2C9 | |
| SCHEMBL1579814 | 0.83 | TBXAS1 (0.48) | KDM4EEPHX2TBXAS1CYP3A4CYP2C9 | |
| SCHEMBL1579813 | 0.83 | TBXAS1 (0.48) | KDM4EEPHX2TBXAS1CYP3A4CYP2C9 | |
| SCHEMBL3544382 | 0.83 | ALDH1A1 (0.61) | KDM4EEPHX2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3549405 | 0.83 | ALDH1A1 (0.61) | KDM4EEPHX2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3544381 | 0.83 | ALDH1A1 (0.61) | KDM4EEPHX2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL57683 | 0.82 | CYP3A4 (0.63) | EPHX2TBXAS1CYP3A4CYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-4748161-A | Triterpenyl esters of organic acids and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1988-05-31 | — | — | US | claimed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | claimed |
| US-RE42700-E1 | Induction of apoptosis in cancer cells | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-13 | — | — | US | disclosed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| CN-1089086-C | Luminandide medicine | MILLS RANDELL L (US) | 2002-08-14 | — | — | CN | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| CN-1047075-A | Luminandide medicine | MILLS RANDELL L (US) | 1990-11-21 | — | — | CN | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| US-4748161-A | Triterpenyl esters of organic acids and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1988-05-31 | — | — | US | disclosed |
| CN-85109752-A | Preparation triterpenoid organic acid ester and the method that contains the hypolipidemic agents of this compounds | — | 1986-12-17 | — | — | CN | disclosed |
| EP-0166542-A2 | Triterpenyl esters of organic acids, process for their production, and hypolipidemic agents composed of them | AMANO PHARMACEUTICAL CO., LTD. (JP) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | KDM4E 3072/4885EPHX2 273/4885OPRM1 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.